SVF
Level A· Stronger Clinical EvidenceSystematic Review

Stem cell therapy-based approaches in experimental endometriosis: a systematic review.

Suárez-Carrasco I., De Pedro MÁ., Pulido M., Álvarez V., Sánchez-Margallo FM., López E.

Systematic Review on Chronic Inflammation, Immune Modulation, published in Reprod Biol Endocrinol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Reprod Biol Endocrinol (2026)
Country
England
Reported sample size
—
PMID
41998676
DOI
10.1186/s12958-026-01553-w

Abstract (original English)

BACKGROUND: Stem cell-based therapies have emerged as a promising approach for endometriosis due to their regenerative and immunomodulatory properties. Although numerous preclinical studies have reported beneficial effects, no systematic synthesis has yet evaluated their impact, the models employed and associated biomarkers. Therefore, the aim of this systematic review is to synthesise all available preclinical evidence (both in vitro and in vivo) assessing stem cell-based therapies and stem cell-derived products in experimental models of endometriosis. METHODS: Following PRISMA guidelines, PubMed, Scopus and Web of Science were searched from 1 January 2015 up to 11 February 2025. Preclinical studies (in vitro and in vivo) evaluating stem cell-based therapies in experimental models of endometriosis were included. Data were extracted regarding the models employed, cell sources, analysed biomarkers and reported cellular outcomes. RESULTS: Twenty preclinical studies were included, employing a wide range of in vitro models (most commonly endometriotic cells) and predominantly murine in vivo models induced by intraperitoneal injection of uterine tissue. Adipose-derived stem cells (ADSCs) and bone marrow-mesenchymal stem cells (BMMSCs) were the most frequently investigated cell sources. Across the studies, VEGFA, TNFA, metalloproteinases (MMPs) and components of the PI3K/AKT/mTOR pat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
FemaleEndometriosisHumansAnimalsStem Cell TransplantationDisease Models, AnimalMesenchymal Stem Cell TransplantationMesenchymal Stem Cells
Chronic InflammationImmune Modulation
View on PubMedDOI

Related research